Be Biopharma Announces Preclinical Data for Novel Engineered B Cell Medicine for the Potential Treatment of Hypophosphatasia September 30, 2024
FDA Grants Orphan Drug Designation for BE-101, a Novel Engineered B Cell Medicine, for the Treatment of Hemophilia B June 4, 2024
Be Biopharma Announces New Preclinical Data for Novel B Cell Medicine for the Potential Treatment of Hypophosphatasia May 13, 2024
